2011 ACC VIDEO: Cost Analysis Substituting Dabigatran for Warfarin


Dr. Julie Atay discusses the two main objectives of her poster which evaluated the cost analysis of substituting Dabigatran for Warfarin.

Dr. Julie Atay discusses her poster, "Cost Analysis of Substituting Dabigatran for Warfarin in an Anticoagulant Management Program," at ACC's 60th Annual Scientific Sessions. Dr. Atay provides a quick explanation about the two objectives her colleagues and she were evaluating: 1) The percentage of patients already on Warfarin who qualified to be on Dabigatran; and 2) The direct costs associated with switching patients from Warfarin to Dabigatran.

Related Videos
Deepak Bhatt, MD, MPH | Credit: Mount Sinai
Robert Wood, MD | Credit: LinkedIn
Marla Dubinsky, MD | Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.